162 related articles for article (PubMed ID: 21732930)
1. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
Richardson PG; Laubach J; Mitsiades CS; Schlossman R; Hideshima T; Redman K; Chauhan D; Ghobrial IM; Munshi N; Anderson KC
Br J Haematol; 2011 Sep; 154(6):755-62. PubMed ID: 21732930
[TBL] [Abstract][Full Text] [Related]
2. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification in the era of novel therapies.
San-Miguel J; Mateos MV; Gutierrez NC
Cancer J; 2009; 15(6):457-64. PubMed ID: 20010164
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
6. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Lonial S; Cavenagh J
Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
[TBL] [Abstract][Full Text] [Related]
7. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
8. New developments in post-transplant maintenance treatment of multiple myeloma.
Liu H; McCarthy P
Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
10. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of novel combinations for induction therapy in multiple myeloma.
Voorhees PM; Orlowski RZ
Clin Lymphoma Myeloma; 2006 Jul; 7(1):33-41. PubMed ID: 16879768
[TBL] [Abstract][Full Text] [Related]
12. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.
Offidani M; Corvatta L; Morabito F; Gentile M; Musto P; Leoni P; Palumbo A
Expert Opin Investig Drugs; 2011 Jun; 20(6):779-93. PubMed ID: 21470070
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.
Brioli A; Tacchetti P; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2014 May; 14(5):581-94. PubMed ID: 24579569
[TBL] [Abstract][Full Text] [Related]
14. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A; Melchor L; Cavo M; Morgan GJ
Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
[TBL] [Abstract][Full Text] [Related]
15. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
Siegel DS; Vij R; Jakubowiak AJ
Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
[TBL] [Abstract][Full Text] [Related]
16. High-risk Multiple Myeloma: Definition and Management.
Joseph NS; Gentili S; Kaufman JL; Lonial S; Nooka AK
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S80-S87. PubMed ID: 28760306
[TBL] [Abstract][Full Text] [Related]
17. New insights into therapeutic targets in myeloma.
Anderson KC
Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
[TBL] [Abstract][Full Text] [Related]
18. Fundamentals in the management of multiple myeloma.
Fadilah SA
Med J Malaysia; 2010 Sep; 65(3):231-9. PubMed ID: 21939177
[TBL] [Abstract][Full Text] [Related]
19. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.
Avet-Loiseau H; Facon T
Leukemia; 2018 Jun; 32(6):1267-1276. PubMed ID: 29720731
[TBL] [Abstract][Full Text] [Related]
20. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Catley L; Tai YT; Chauhan D; Anderson KC
Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
